The effect of nebivolol on P wave duration and dispersion in patients with Behçet's disease; a prospective single-arm controlled study [Behçet hastali{dotless}gi{dotless}nda nebivololün P dalga süresi ve P dalga dispersiyonuna etkisi; prospektif, tek grup kontrollü çali{dotless}şma]

PubMed ID: 23996803Objective: Behçet's disease (BD) is a chronic multi-system disease presenting with recurrent oral and genital ulceration, and relapsing uveitis. Left ventricular diastolic dysfunction, ventricular arrhythmia and sudden cardiac death have been documented in BD. P wave dispersion (PD) has been reported to be associated with inhomogeneous and discontinuous propagation of sinus impulses. PD has been reported to be longer in patients with BD. Nebivolol, besides its selective beta1-blocking activity, causes an endothelium dependent vasodilatation through nitric oxide release. In this study, we searched for the effects of nebivolol on P wave duration and dispersion in patients with BD. Methods: This study was designed as prospective single-arm controlled study. We prospectively studied 35 Behçet's patients who were diagnosed according to the International Study Group criteria. Patients received 5 mg nebivolol per day for 3 months. The patients were evaluated with 12-leads electrocardiography at baseline and after for 3-month therapy. The difference between maximum and minimum P wave durations was defined as PD. The paired samples t test, Wilcoxon test were used for statistical analysis. Results: A significant decrease was observed in PD after therapy period (62.85±21.62 vs. 44.28±18.03 msec, p=0.001). No adverse effects were observed in treatment period. Conclusion: BD is associated with prolonged P wave duration and dispersion. We have shown for the first time that nebivolol causes a significant decrease in maximum P wave duration and PD in patients with BD. However, further comprehensive studies are needed to determine the long-term effects of nebivolol. © 2013 by AVES Yayi{dotless}nci{dotless}li{dotless}k Ltd

Clinical evaluation of roxithromycin: A double-blind, placebo-controlled and crossover trial in patients with acne vulgaris

We clinically evaluated roxithromycin (ROM) in a double blind, placebo-controlled, and crossover trial in patients with inflammatory acne. Patients with inflammatory acne who were attending our outpatient clinic for treatment and who had not received topical or systemic treatment for the previous month were enrolled in this study. Patients were randomly separated into two groups. Group I consisted of 26 patients. The patients received 2 x 150 mg/day ROM orally in the first period and 2 x I placebo tablets/day in the second period. Group 11 consisted of 20 patients. These patients received 2 x I placebo tablets/day in the first period and 2 x 150 mg/day ROM orally in the second period. The first period was the first four weeks, and then there was a washout period of two weeks (5th and 6th). The second period was the next four weeks (7th to 10th weeks) after the washout period. Median acne scores had clearly decreased in both groups at the end of the study. Differences of median acne scores were statistically significant in both groups between at baseline and at the end of the study (p< 0.001). The results showed that ROM is a safe and effective alternative in the treatment of inflammatory acne with few side effects and good compliance

Association between isolated female acne and insulin resistance: A prospective study

PubMed ID: 26373866Background: acne is one of the manifestations of the polycystic ovary syndrome (PCoS). Nowadays hyperinsulinemia and insulin resistance are well-known characteristics of PCoS. the aim of this study was to investigate the relation between isolated female acne and insulin resistance and to determine the effect of hyperandrogenemia in this possible relationship. METHODS: Forty ive women with acne and 24 healthy women aged 25-40 were included in the study. The global acne grading system (GAGS) was used to evaluate acne severity. Blood samples were drawn for measurements of hormone proile, basal insulin and fasting blood glucose (FBG). the oral glucose tolerance test (oGtt) was performed on another day. homeostasis model assessment (Homa) score was used to assess insulin resistance (ir). all subjects underwent abdominopelvic sonography. reSUltS: thirty-six women with acne and 24 healthy women were analyzed after exclusion. Fifteen (42%) patients had moderate acne, 11 (30%) had severe acne and 10 (28%) had very severe acne. Basal insulin, FBG, AUC glucose, AUC insulin and HOMA values were signiicantly higher in patients with acne when compared with the control group (P<0.05). after excluding patients with hyperandrogenemia, we compared the patients (N.=22) and control group with regard to ir; the serum basal insulin, aUC-insulin and aUC-glucose as well as Homa score were still signiicantly higher in patients (P<0.05). CoNClUSioNS: We concluded that there is a relationship between female acne and ir. this association is independent of hyperandrogenemia. anti-insulin drugs may an adjunctive treatment of female acne. © 2015 Edizioni Minerva Medica

Synovial nitric oxide concentrations are increased and correlated with serum levels in patients with active Behcet's disease: a pilot study

Behcet's disease (BD) is a relapsing immuno-inflammatory vasculitis of unknown etiology characterized by endothelial dysfunction. Articular symptoms and signs are present in about 75% of cases and characterized by seronegative arthritis and nonspecific synovitis. We demonstrated that both serum and erythrocyte nitric oxide (NO center dot) levels, the most abundant free radical in the body, were elevated in BD and associated with disease activity. This study further investigated NO center dot levels in the synovial fluid and serum from patients with active and inactive BD. A total of 23 BD patients with articular involvement ( 14 men and 9 women) satisfying International Study Group criteria and 15 age- and sex-matched healthy control subjects ( 9 men and 6 women) undergoing elective arthroscopy were included in this case-control investigation. The synovial fluid and serum were obtained from BD patients and controls. Clinical and laboratory findings including neutrophil count and erythrocyte sedimentation rate (ESR) were used to classify BD patients as active (n = 11) or inactive (n = 12). Synovial as well as serum NO center dot levels were compared between the groups and correlation analysis was performed. Acute phase reactant levels were significantly higher ( for each, p 0.05). Active BD patients had significantly higher serum NO center dot levels ( 38.84 +/- 9.15 mu mol/l) than inactive patients (30.91 +/- 5.88 mu mol/ l, p = 0.018) and control subjects (28.86 +/- 5.91 mu mol/ l, p=0.002). In addition, synovial NO center dot levels were positively correlated with serum levels (r(2) = 0.621, p< 0.001). Increased synovial NO center dot levels in active BD patients probably reflect a nonspecific inflammatory process of the synovium and, therefore, arthralgia and arthritis as a common finding of BD